Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?

J Diabetes Res. 2017:2017:7583506. doi: 10.1155/2017/7583506. Epub 2017 Sep 10.

Abstract

Background: The incretin effect is impaired in patients with type 2 diabetes.

Aim: To assess the relation between the incretin hormone GLP-1 and the prediabetic subtypes: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and the combined IFG/IGT to investigate whether a low GLP-1 response may be a predictor of prediabetes in adults.

Method: 298 articles were found using a broad search phrase on the PubMed database and after the assessment of titles and abstracts 19 articles were included.

Results and discussion: Studies assessing i-IFG/IFG and i-IGT/IGT found both increased, unaltered, and reduced GLP-1 levels. Studies assessing IFG/IGT found unaltered or reduced GLP-1 levels. When assessing the five studies with the largest sample size, it clearly suggests a decreased GLP-1 response in IFG/IGT subjects. Several other factors (BMI, glucagon, age, and nonesterified fatty acids (NEFA)), including medications (metformin), may also influence the secretion of GLP-1.

Conclusion: This review suggests that the GLP-1 response is a variable in prediabetes possibly due to a varying GLP-1-secreting profile during the development and progression of type 2 diabetes or difference in the measurement technique. Longitudinal prospective studies are needed to assess whether a reduced GLP-1 response is a predictor of diabetes.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / epidemiology
  • Disease Progression
  • Glucagon-Like Peptide 1 / blood*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Prediabetic State / blood*
  • Prediabetic State / diagnosis
  • Prediabetic State / drug therapy
  • Prediabetic State / epidemiology
  • Risk Factors

Substances

  • Biomarkers
  • Blood Glucose
  • Hypoglycemic Agents
  • Glucagon-Like Peptide 1